Atlas Trials

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

Clinical trial NCT05059106 · UNKNOWN

Trial details

NCT number
NCT05059106
Sponsor
Federal University of Espirito Santo
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
SARS-CoV-2
Start date
2021-06-01
Primary completion
2022-06-01
Enrollment
29637

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.